Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 334 phase 3 study for prevention of episodic migraine
NL-OMON43798Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erenumab in migraine and episodic migraine (3 arms), sponsored by Amgen. Primary endpoint: Change from baseline in mean monthly migraine days. Started Mar 2016; status: active, not recruiting.
02
Drugs
erenumab
03
Conditions
migraineepisodic migraine
Beyond the preview
Go deeper on NL-OMON43798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43798.